Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03618030 · ClinicalTrials.gov registry record · Phase 3
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3 study of ADHD, sponsored by Purdue Pharma, Canada.
- Completed
- Registry status
- Phase 3
- Development phase
- 288
- Enrollment target
- 8
- Study locations
NCT03618030: Completed Phase 3 study of ADHD, sponsored by Purdue Pharma, Canada.
NCT03618030 is a Phase 3 study of ADHD that has completed, run by Purdue Pharma, Canada. The registered enrollment target is 288 participants, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (55% higher). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03618030, a Phase 3 study of ADHD, has completed, sponsored by Purdue Pharma, Canada.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 288 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
Primary Outcome
PERMP-T measures the number of completed and number of attempted math problems completed during a 10 minute test. The scale ranges from 0 to 800, with a higher score indicating a better outcome.
Conditions Studied
Interventions
- DRUG Placebo oral capsules
- DRUG PRC-063 oral capsules
Study Locations (8)
Florida
- Meridien Research Inc. - Bradenton
- Meridien Research - Lakeland
- Meridien Research Inc. - Maitland
Massachusetts
- South Shore Psychiatric Services - Hingham
Nevada
- Center for Psychiatry and Behavioral Medicine - Las Vegas
North Carolina
- Center for Psychiatry and Behavioral Medicine - Durham
Pennsylvania
- Penn State Health Milton S. Hershey Medical Center - Hershey
Texas
- Bayou City Research - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 288 participants |
| Start Date | 2018-08-21 |
| Est. Completion | 2019-07-05 |
| Phase | Phase 3 |
What the finished NCT03618030 record still lists
NCT03618030 is an interventional study that assigns participants to a tested intervention. The registered 288 participants enrollment target is mid-sized for trials with a published cap, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (55% higher).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo oral capsules is the first listed.
NCT03618030 lists 8 locations in 6 states (Florida, Massachusetts, Nevada).
Frequently Asked Questions
What is clinical trial NCT03618030 about?
NCT03618030 is a clinical study titled "PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in adults
What is the current status of trial NCT03618030?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 288 participants. The study started on 2018-08-21. Estimated completion is 2019-07-05.
What conditions does trial NCT03618030 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT03618030?
The interventions under investigation include: Placebo oral capsules (DRUG), PRC-063 oral capsules (DRUG).
Who is sponsoring clinical trial NCT03618030?
This trial is sponsored by Purdue Pharma, Canada, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03618030 being conducted?
This trial has 8 study locations across Florida, Massachusetts, Nevada, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03618030's enrollment target sits among peer trials
288 13th of 75 higher than 62 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
RECRUITING · Phase 3
-
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
ACTIVE NOT RECRUITING · Phase 3
-
Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Safety and Efficacy Study of Dexmethylphenidate in Children With ADHD
COMPLETED · Phase 3
-
Study to Assess Satisfaction With Modafinil Treatment in Children and Adolescents With ADHD
COMPLETED · Phase 3
-
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
- NCT03741777 · 288 participants · NA
Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume
- NCT03937635 · 288 participants · Phase 3
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
- NCT04621877 · 288 participants · NA
Lay-Delivered Behavioral Activation in Senior Centers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI